Viridian Therapeutics, Inc.

Direct answer

Viridian Therapeutics, Inc. is publicly traded on NASDAQ under the ticker VRDN.

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation,...

Can you invest in Viridian Therapeutics, Inc.?

Yes. Viridian Therapeutics, Inc. trades publicly on NASDAQ as VRDN.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Viridian Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.